Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/27881
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16926/19260 (88%)
Visitors : 7616135      Online Users : 219
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27881


    Title: Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-gamma-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities
    Authors: Yeh, Jwu-Lai
    Hsu, Jong-Hau
    Liang, Jyh-Chong
    Chen, Ing-Jun
    Liou, Shu-Fen
    Contributors: 藥學系
    Keywords: Dihydropyridine Calcium Channel Blockers
    Vascular Smooth Muscle Cells
    Lipopolysaccharide/Interferon-Gamma
    Date: 2013-02
    Issue Date: 2014-05-26 10:47:28 (UTC+8)
    Publisher: Elsevier Ireland Ltd
    Abstract: Objective: Inflammation is an important molecular basis of atherosclerosis. Recent studies have shown that dihydropyridine calcium channel blockers (CCBs) can exert potent anti-inflammatory effects in models of vascular dysfunction. The purpose of the present study was to evaluate anti-inflammatory effects and mechanisms of lercanidipine and labedipinedilol-A, new generation dihydropyridine CCBs, in rat vascular smooth muscle cells (VSMCs) exposed to lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma).Methods and results: MTT, Griess reagent, RT-PCR, ELISA, gelatin zymography, immunocytochemistry and Western blotting were employed. We found that lercanidipine and labedipinedilol-A attenuated production of NO, ROS and TNF-alpha from LPS/IFN-gamma-stimulated VSMCs. In addition, they both diminished the LPS/IFN-gamma-induced expression of iNOS protein and mRNA, with attenuation of HMGB1 cytosolic translocation and subsequent extracellular release. Furthermore, they down-regulated MMP-2/MMP-9 activities, whereas expression of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), an inhibitor of MMP-9, was up-regulated. Finally, we found that lercanidipine and labedipinedilol-A inhibited the nuclear translocation of NF-kappa B and suppressed the phosphorylation of JNK, p38 MAPK and Akt.Conclusion: Lercanidipine and labedipinedilol-A can exert their anti-inflammatory effects through suppression of NO, ROS and TNF-alpha through down-regulation of iNOS, MMP-2/MMP-9, and HMGB1, with inhibition of signaling transduction of MAPKs, Akt/IkB-alpha and NF-kappa B pathways. These findings implicate a valuable role of new generation dihydropyridine CCBs lercanidipine and labedipinedilol-A for the treatment of inflammatory vascular diseases. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
    Appears in Collections:[Dept. of Pharmacy] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML414View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback